For instance, in POPLAR and OAK trials, advanced NSCLC patients with higher PDL-1 expression treated with atezolizumab derived higher survival benefits over chemotherapy [21,22] Conversely, in advanced UC, the issue of whether ICI has survival superiority over chemotherapy varied among different agents. The gene discussed is CD274; the disease is non-small cell lung carcinoma.